|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prazosin#Adult Indications and Dosage]] |
| {{Prazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| The dose of MINIPRESS should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:
| |
| | |
| ===Initial Dose===
| |
| | |
| 1 mg two or three times a day (see [[Prazosin warnings|WARNINGS]].)
| |
| ===Maintenance Dose===
| |
| | |
| Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a daily dose of 40 mg given in divided doses. After initial titration some patients can be maintained adequately on a twice daily dosage regimen. | |
| | |
| ===Use With Other Drugs===
| |
| | |
| When adding a diuretic or other antihypertensive agent, the dose of MINIPRESS should be reduced to 1 mg or 2 mg three times a day and retitration then carried out.
| |
| | |
| Concomitant administration of MINIPRESS with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking MINIPRESS.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |